IPF patient survey provides new insights into disease burden and patient experience one decade after the approval of the first antifibrotics for IPF Clinical abstract reviews the ability of Bayesian ...

Dr. Brent Carter's lab does fundamental research in idiopathic pulmonary fibrosis (IPF) and asbestosis. They focus primarily on the role of macrophages (monocyte-derived macrophages) in driving ...

A Wnt/β-catenin pathway agonist under development by Surrozen appears to be effective against idiopathic pulmonary fibrosis (IPF) in mouse models, according to new data. The results, published April 2 ...

NASHVILLE, Tenn. and CAMBRIDGE, England, May 13, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company with development efforts focused on new ...

TCGFB, a private biotech founded by healthcare VC The Column Group, is tapping California biotech Surrozen to discover antibodies for idiopathic pulmonary fibrosis, according to a Nov. 4 release.

A recent study from China has reported that Cordyceps sinensis (CS), a traditional Chinese medicinal fungus, can ameliorate idiopathic pulmonary fibrosis (IPF) in mice by inhibiting ...

The annual number of publications on macrophages and pulmonary fibrosis jumped during 2017 and 2020, with signs pointing to more focus on research in these fields. Between January 1990 and July 2023, ...

UVA Health researchers have discovered a potential way to predict which patients with severe COVID-19 are likely to recover well and which are likely to suffer "long-haul" lung problems. That finding ...

IPF is a chronic lung disease with fibrous tissue formation, leading to respiratory decline and poor prognosis, affecting mainly older adults. Diagnosis is challenging due to its exclusionary nature, ...

PureTech Presents Research Highlighting Burden of Idiopathic Pulmonary Fibrosis (IPF) and Use of a Bayesian Statistical Analysis for LYT-100 (Deupirfenidone) at CHEST 2024 Annual Meeting IPF patient ...